Pricing Log in Create free account

Genelux Corporation (GNLX) vs ImmuCell Corporation (ICCC)

Genelux Corporation and ImmuCell Corporation are both Biotechnology companies. Genelux Corporation and ImmuCell Corporation are of similar size ($93.2M and $88.2M). Genelux Corporation has negative trailing earnings, so its P/E is not meaningful; ImmuCell Corporation trades at 123×. ImmuCell Corporation has the higher net margin (2.57% vs 0.00%) and the higher return on invested capital (7.84% vs 0.00%). Across the 16 metrics below, ImmuCell Corporation leads on 14 and Genelux Corporation on 2.

Valuation

Metric GNLX ICCC Biotechnology median
P/E n/m 122.93 10.96
P/S 7.80 3.07 9.52
P/B 5.44 3.00 2.23
Price to free cash flow n/m 22.28 25.69
EV/EBITDA n/m 14.90 0.68
EV/Sales 6.89 3.06 9.00
Earnings yield (44.10%) 0.81% (32.09%)
Free cash flow yield (32.72%) 4.49% (22.62%)

Profitability

Metric GNLX ICCC Biotechnology median
Gross margin (3.42%) 40.32% 68.51%
Operating margin 0.00% 12.60% 0.00%
Net margin 0.00% 2.57% 0.00%
Free cash flow margin 0.00% 13.79% 0.00%
Return on equity (177.93%) 2.57% (50.12%)
Return on assets (121.80%) 1.69% (45.12%)
Return on invested capital 0.00% 7.84% 0.00%

Growth

Metric GNLX ICCC Biotechnology median
Revenue growth (TTM) — 8.49% 6.78%
EPS growth (last fiscal year) 9.47% 53.85% 29.88%
Revenue growth, 5-year CAGR — 12.50% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNLX ICCC Biotechnology median
Debt to equity 0.00 0.26 0.00
Current ratio 2.39 4.75 4.74
Net debt to EBITDA 0.44 1.19 1.01

Dividend

Metric GNLX ICCC Biotechnology median
Dividend yield — — 0.40%
Payout ratio — — —

Size

Metric GNLX ICCC Biotechnology median
Market cap 88.23m 93.18m 166.39m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack